Vaccinomics to Design a Multiepitope Vaccine against Legionella pneumophila
- PMID: 36164443
- PMCID: PMC9509222
- DOI: 10.1155/2022/4975721
Vaccinomics to Design a Multiepitope Vaccine against Legionella pneumophila
Abstract
Legionella pneumophila is found in the natural aquatic environment and can resist a wide range of environmental conditions. There are around fifty species of Legionella, at least twenty-four of which are directly linked to infections in humans. L. pneumophila is the cause of Legionnaires' disease, a potentially lethal form of pneumonia. By blocking phagosome-lysosome fusion, L. pneumophila lives and proliferates inside macrophages. For this disease, there is presently no authorized multiepitope vaccine available. For the multi-epitope-based vaccine (MEBV), the best antigenic candidates were identified using immunoinformatics and subtractive proteomic techniques. Several immunoinformatics methods were utilized to predict B and T cell epitopes from vaccine candidate proteins. To construct an in silico vaccine, epitopes (07 CTL, 03 HTL, and 07 LBL) were carefully selected and docked with MHC molecules (MHC-I and MHC-II) and human TLR4 molecules. To increase the immunological response, the vaccine was combined with a 50S ribosomal adjuvant. To maximize vaccine protein expression, MEBV was cloned and reverse-translated in Escherichia coli. To prove the MEBV's efficacy, more experimental validation is required. After its development, the resulting vaccine is greatly hoped to aid in the prevention of L. pneumophila infections.
Copyright © 2022 Ahitsham Umar et al.
Conflict of interest statement
The authors report no conflicts of interest for this work.
Figures
Similar articles
-
Proteome Exploration of Legionella pneumophila To Identify Novel Therapeutics: a Hierarchical Subtractive Genomics and Reverse Vaccinology Approach.Microbiol Spectr. 2022 Aug 31;10(4):e0037322. doi: 10.1128/spectrum.00373-22. Epub 2022 Jul 12. Microbiol Spectr. 2022. PMID: 35863001 Free PMC article.
-
Recombinant PAL/PilE/FlaA DNA vaccine provides protective immunity against Legionella pneumophila in BALB/c mice.BMC Biotechnol. 2020 May 18;20(1):28. doi: 10.1186/s12896-020-00620-3. BMC Biotechnol. 2020. PMID: 32423439 Free PMC article.
-
CD8+ T Cells Directed Against a Peptide Epitope Derived From Peptidoglycan-Associated Lipoprotein of Legionella pneumophila Confer Disease Protection.Front Immunol. 2020 Dec 8;11:604413. doi: 10.3389/fimmu.2020.604413. eCollection 2020. Front Immunol. 2020. PMID: 33363545 Free PMC article.
-
Viewing Legionella pneumophila Pathogenesis through an Immunological Lens.J Mol Biol. 2019 Oct 4;431(21):4321-4344. doi: 10.1016/j.jmb.2019.07.028. Epub 2019 Jul 25. J Mol Biol. 2019. PMID: 31351897 Free PMC article. Review.
-
Legionella pneumophila: an aquatic microbe goes astray.FEMS Microbiol Rev. 2002 Jun;26(2):149-62. doi: 10.1111/j.1574-6976.2002.tb00607.x. FEMS Microbiol Rev. 2002. PMID: 12069880 Review.
Cited by
-
Immunoinformatic-guided designing and evaluating protein and mRNA-based vaccines against Cryptococcus neoformans for immunocompromised patients.J Genet Eng Biotechnol. 2023 Oct 26;21(1):108. doi: 10.1186/s43141-023-00560-3. J Genet Eng Biotechnol. 2023. PMID: 37882985 Free PMC article.
-
Computational design and evaluation of mRNA- and protein-based conjugate vaccines for influenza A and SARS-CoV-2 viruses.J Genet Eng Biotechnol. 2023 Nov 15;21(1):120. doi: 10.1186/s43141-023-00574-x. J Genet Eng Biotechnol. 2023. PMID: 37966525 Free PMC article.
References
-
- Saad M., Castiello F. R., Faucher S. P., Tabrizian M. Introducing an SPRi-based titration assay using aptamers for the detection of Legionella pneumophila. Sensors and Actuators B: Chemical . 2021;351:p. 130933.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials